CMS grants AquaBeam transitional pass-through payment status
PROCEPT BioRobotics announced CMS transitional pass-through payment status for Aquablation therapy delivered by AquaBeam.
Evidence notes
- The payment status applied through the 2020 outpatient prospective payment system.
- AquaBeam delivers image-guided robotic waterjet removal of prostate tissue for BPH.
- The reimbursement decision supported use of the exact system in outpatient care.
Company context
PROCEPT BioRobotics develops surgical robotic systems for Aquablation therapy, including image-guided robotic waterjet treatment for benign prostatic hyperplasia.